The acquisition of Assertio Holdings by Garda Therapeutics is expected to close in Q3 2026, creating significant value for shareholders through synergies and cost savings. The deal is valued at $117 million, including $115 million in cash and $2 million in CVRs. The transaction is expected to be accretive to earnings per share and free cash flow. Investors should monitor the closing of the deal and the integration of the two companies.
Price Chart
Executive Summary
Assertio Holdings (ASRT) has agreed to be acquired by Garda Therapeutics in an all-cash deal valued at $117 million, including a $18.00 per share offer and contingent value rights (CVRs) tied to future milestones. The transaction is expected to close in Q3 2026, subject to regulatory approvals and other customary conditions.
Key Financial Metrics
Key Facts
- Garda Therapeutics will acquire Assertio Holdings in an all-cash transaction
- The deal includes a $18.00 per share offer and contingent value rights (CVRs) tied to future milestones
- The transaction is valued at $117 million, including $115 million in cash and $2 million in CVRs
- The deal is expected to close in Q3 2026, subject to regulatory approvals and other customary conditions
- The acquisition is expected to create significant value for shareholders through synergies and cost savings
Financial Impact
The transaction is valued at $117 million, including $115 million in cash and $2 million in CVRs
Risk Factors
- Regulatory approvals may delay or prevent the closing of the deal
- Integration of the two companies may be challenging and may not achieve expected synergies
- The CVRs are contingent on future milestones and may not be realized
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-041236 |
| Document: tm2611405d1_ex10-1.htm | 0001104659-26-041236 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 7, 2026 15w ago | 25-NSE | — | awaiting T+20 | — | — |
Jun 26, 2026 17w ago | 15-12G | $23.50 | awaiting T+20 | — | — |
Jun 18, 2026 18w ago | EFFECT | $23.50 | awaiting T+20 | — | — |
Jun 16, 2026 18w ago | 8-K | $23.50 | awaiting T+20 | — | — |
May 18, 2026 23w ago | 8-K | $23.32 $23.50 | ▲ +0.77% | ▼ −0.81% | — |
May 8, 2026 24w ago | 8-K | $22.50 $23.44 | ▲ +4.18% | ▲ +4.15% | — |
May 5, 2026 24w ago | 8-K | $22.16 $23.45 | ▲ +5.82% | ▲ +0.87% | — |
May 4, 2026 25w ago | 8-K | $21.61 $23.43 | ▲ +8.42% | ▲ +2.78% | — |
Apr 29, 2026 25w ago | 8-K | $18.43 $23.44 | ▲ +27.18% | ▲ +21.96% | — |
Apr 9, 2026 28w ago | 8-K | $18.02 $22.20 | ▲ +23.20% | ▲ +15.63% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers